TSCAN THERAPEUTICS INC (TCRX)
US89854M1018 - Common Stock
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
WALTHAM, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
Investors Snatch TCRX 6.7% Lower Than Its Secondary Stock Offering
TScan Therapeutics Announces Closing of Upsized Public Offering
TScan Therapeutics Announces Closing of Upsized Public Offering
WALTHAM, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for at least one TCR-T in the...
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial development
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
WALTHAM, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With
Although lesser-known ideas present high risks, these cheap stocks under $10 could be intriguing for the calculating speculator.
TCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023
TCRX stock results show that TScan Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
TCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips TScan Therapeutics (NASDAQ:TCRX) just reported results for the fourth quarter o...
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the Tandem Meetings of ASTCT and CIBMTR; 8/8 (100%) patients in treatment arms are relapse-free and show complete donor chimerism
TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR
TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR
All eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or...
TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
TScan’s abstract selected by the Tandem Meetings to receive a Best Abstracts Award Company to discuss the potential implications of initial data from a...
TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development
TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development
WALTHAM, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
TScan Therapeutics appoints CFO (NASDAQ:TCRX)
TScan Therapeutics appointed Jason Amello as CFO. Amello joins from Candel Therapeutics
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR
TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR
Presentation to include additional results from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies WALTHAM, Mass., Jan....
TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress
TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress
Reported positive initial data from Phase 1 heme program at the 65th American Society of Hematology (ASH) Annual Meeting Clearance of INDs for four...